Objective: Although advances in disease-modifying therapies have improved rheumatoid arthritis (RA) management, many patients still require total hip or knee arthroplasty. Long-term data on baseline characteristics and treatment patterns of RA patients undergoing arthroplasty in China are scarce. This study aimed to investigate time trends in baseline demographic, clinical, laboratory, and treatment parameters of RA patients undergoing THA and TKA between 2002 and 2022.
Methods: A retrospective study of consecutive THAs and TKAs for RA patients between 2002 and 2022 was conducted at a single center. The preoperative patient demographics, clinical and laboratory parameters were collected. All joints were divided into 2002–2011 and 2012–2022 groups, THA and TKA groups, juvenile-onset rheumatoid arthritis (JORA) (0–16 years), adult-onset rheumatoid arthritis (AORA) (16–60 years), and late-onset rheumatoid arthritis (LORA) (≥ 60 years) groups, respectively. The intergroup comparisons were performed.
Results: A total of 1363 primary TKAs in 897 patients with RA and 561 hips in 511 patients with RA were included. The number of arthroplasties performed annually from 2002 to 2022 demonstrated a significantly increasing trend. The use of glucocorticoids (GCs) before surgery demonstrated a significant decreasing trend while conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs) + targeted synthetic DMARDs (tsDMARDs) demonstrated an increasing trend. Comparison by time period (2002–2011 vs. 2012–2022) showed that the percentage of preoperative use of csDMARDs and bDMARDs + tsDMARDs was significantly higher and GCs were significantly higher in the 2002–2011 group.
Conclusions: The number of THAs and TKAs performed annually from 2002 to 2022 demonstrated a significantly increasing trend in a tertiary care center for musculoskeletal diseases. In contrast, a significantly increasing trend for the percentage of preoperative use of csDMARDs and bDMARDs + tsDMARDs and a significantly decreasing trend for preoperative use of GCs and inflammatory markers was identified.
| [1] |
C. M. Weyand and J. J. Goronzy, “The Immunology of Rheumatoid Arthritis,” Nature Immunology 22, no. 1 (2021): 10–18, https://doi.org/10.1038/s41590-020-00816-x.
|
| [2] |
A. I. Venetsanopoulou, Y. Alamanos, P. V. Voulgari, and A. A. Drosos, “Epidemiology and Risk Factors for Rheumatoid Arthritis Development,” Mediterranean Journal of Rheumatology 34, no. 4 (2023): 404–413.
|
| [3] |
Y. Gao, Y. N. Gao, M. J. Wang, et al., “Efficacy and Safety of Tofacitinib Combined With Methotrexate in the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis,” Heliyon 9, no. 5 (2023): e15839.
|
| [4] |
V. M. Holers, K. A. Kuhn, M. K. Demoruelle, et al., “Mechanism-Driven Strategies for Prevention of Rheumatoid Arthritis,” Rheumatology & Autoimmunity 2 (2022): 109–119, https://doi.org/10.1002/rai2.12043.
|
| [5] |
K. Bonek, L. Roszkowski, M. Massalska, W. Maslinski, and M. Ciechomska, “Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment,” Cells 10, no. 4 (2021): 323, https://doi.org/10.3390/cells10020323.
|
| [6] |
B. L. Young, S. L. Watson, J. L. Perez, G. McGwin, J. A. Singh, and B. A. Ponce, “Trends in Joint Replacement Surgery in Patients With Rheumatoid Arthritis,” Journal of Rheumatology 45 (2018): 158–164.
|
| [7] |
S. Asai, T. Takemoto, N. Takahashi, T. Oguchi, N. Ishiguro, and T. Kojima, “Fifteen-Year Trends in the Number and Age of Patients With Rheumatoid Arthritis Undergoing Total Knee and Hip Arthroplasty: A Comparison Study With Osteoarthritis,” Modern Rheumatology 31, no. 3 (2021): 768–771, https://doi.org/10.1080/14397595.2020.1812794.
|
| [8] |
S. Asai, N. Takahashi, N. Asai, et al., “Characteristics of Patients With Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-Year Trend Analysis (2004-2017),” Modern Rheumatology 30, no. 4 (2020): 657–663, https://doi.org/10.1080/14397595.2019.1649111.
|
| [9] |
A. J. Kurdi, B. A. Voss, T. H. Tzeng, S. L. Scaife, M. M. El-Othmani, and K. J. Saleh, “Rheumatoid Arthritis vs Osteoarthritis: Comparison of Demographics and Trends of Joint Replacement Data From the Nationwide Inpatient Sample,” American Journal of Orthopedics 47, no. 7 (2018), https://doi.org/10.12788/ajo.2018.0050.
|
| [10] |
S. S. Tao, J. Tang, Y. C. Liu, S. Z. Xu, Z. Chen, and H. F. Pan, “Evolutionary Patterns and Future Perspectives of Joint Replacement in Arthritis Patients: A Comprehensive Analysis of Findings Over the Past Decades,” EFORT Open Reviews 10, no. 9 (2025): 646–659.
|
| [11] |
R. E. Zwartelé, S. Witjes, H. C. Doets, T. Stijnen, and R. G. Pöll, “Cementless Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review of the Literature,” Archives of Orthopaedic and Trauma Surgery 132 (2012): 535–546.
|
| [12] |
M. A. Plantz, A. E. Sherman, C. H. Miller, K. D. Hardt, and Y. C. Lee, “Outcomes of Total Knee Arthroplasty in Patients With Rheumatoid Arthritis,” Orthopedics 44, no. 5 (2021): e626–e632.
|
| [13] |
S. M. Goodman, B. Johnson, M. Zhang, et al., “Patients With Rheumatoid Arthritis Have Similar Excellent Outcomes After Total Knee Replacement Compared With Patients With Osteoarthritis,” Journal of Rheumatology 43 (2016): 46–53.
|
| [14] |
F. C. Arnett, S. M. Edworthy, D. A. Bloch, et al., “The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis,” Arthritis and Rheumatism 31, no. 3 (1988): 315–324.
|
| [15] |
D. Aletaha, T. Neogi, A. J. Silman, et al., “2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative,” Arthritis & Rheumatism 62, no. 9 (2010): 2569–2581.
|
| [16] |
K. Michaud and F. Wolfe, “Comorbidities in Rheumatoid Arthritis,” Best Practice & Research. Clinical Rheumatology 21 (2007): 885–906.
|
| [17] |
B. T. Fevang, S. A. Lie, L. I. Havelin, L. B. Engesaeter, and O. Furnes, “Reduction in Orthopedic Surgery Among Patients With Chronic Inflammatory Joint Disease in Norway, 1994-2004,” Arthritis and Rheumatism 57 (2007): 529–532.
|
| [18] |
K. Hekmat, L. Jacobsson, J. A. Nilsson, et al., “Decrease in the Incidence of Total Hip Arthroplasties in Patients With Rheumatoid Arthritis-Results From a Well Defined Population in South Sweden,” Arthritis Research & Therapy 13 (2011): R67.
|
| [19] |
A. B. Pedersen, A. Mor, F. Mehnert, R. W. Thomsen, S. P. Johnsen, and M. Nørgaard, “Rheumatoid Arthritis: Trends in Antirheumatic Drug Use, C-Reactive Protein Levels, and Surgical Burden,” Journal of Rheumatology 42, no. 12 (2015): 2247–2254, https://doi.org/10.3899/jrheum.141297.
|
| [20] |
C. D. Poole, P. Conway, A. Reynolds, and C. J. Currie, “The Association Between C-Reactive Protein and the Likelihood of Progression to Joint Replacement in People With Rheumatoid Arthritis: A Retrospective Observational Study,” BMC Musculoskeletal Disorders 9 (2008): 146.
|
| [21] |
T. Matsumoto, J. Nishino, N. Izawa, et al., “Trends in Treatment, Outcomes, and Incidence of Orthopedic Surgery in Patients With Rheumatoid Arthritis: An Observational Cohort Study Using the Japanese National Database of Rheumatic Diseases,” Journal of Rheumatology 44, no. 11 (2017): 1575–1582, https://doi.org/10.3899/jrheum.170046.
|
| [22] |
C. Yu, M. Li, X. Duan, et al., “Chinese Registry of Rheumatoid Arthritis (CREDIT): I. Introduction and Prevalence of Remission in Chinese Patients With Rheumatoid Arthritis,” Clinical and Experimental Rheumatology 36, no. 5 (2018): 836–840.
|
| [23] |
S. Jin, M. Li, Y. Fang, et al., “Chinese Registry of Rheumatoid Arthritis (CREDIT): II. Prevalence and Risk Factors of Major Comorbidities in Chinese Patients With Rheumatoid Arthritis,” Arthritis Research & Therapy 19, no. 1 (2017): 251, https://doi.org/10.1186/s13075-017-1457-z.
|
| [24] |
X. Li, A. Cesta, M. Movahedi, and C. Bombardier, “Late-Onset Rheumatoid Arthritis Has a Similar Time to Remission as Younger-Onset Rheumatoid Arthritis: Results From the Ontario Best Practices Research Initiative,” Arthritis Research & Therapy 24 (2022): 255, https://doi.org/10.1186/s13075-022-02952-1.
|
| [25] |
T. C. Tan, X. Gao, B. Y. Thong, et al., “Comparison of Elderly- and Young-Onset Rheumatoid Arthritis in an Asian Cohort,” International Journal of Rheumatic Diseases 20, no. 6 (2017): 737–745, https://doi.org/10.1111/1756-185X.12861.
|
| [26] |
T. Krams, A. Ruyssen-Witrand, D. Nigon, et al., “Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The ESPOIR Cohort,” Joint, Bone, Spine 83, no. 5 (2016): 511–515, https://doi.org/10.1016/j.jbspin.2015.09.010.
|
| [27] |
A. Patwardhan, “The Utility and Experience With Disease Biomarkers in Juvenile Onset Arthritis vs. Adult Onset Arthritis,” Cureus 11, no. 13 (2019): e5131, https://doi.org/10.7759/cureus.5131.
|
| [28] |
A. Felis-Giemza, K. Chmurzyńska, B. Kołodziejczyk, and A. Gazda, “Revising Diagnosis of Juvenile Idiopathic Arthritis in Adults: A Single-Center Retrospective Study,” Rheumatology International 43, no. 7 (2023): 1307–1311, https://doi.org/10.1007/s00296-023-05293-7.
|
| [29] |
I. Bardan, K. M. Fagerli, J. Sexton, et al., “Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD,” Journal of Rheumatology 50, no. 4 (2023): 538–547, https://doi.org/10.3899/jrheum.220645.
|
RIGHTS & PERMISSIONS
2026 The Author(s). Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.
PDF
(2130KB)
